Population pharmacokinetics of a three-day chloroquine treatment in patients with Plasmodium vivax infection on the Thai-Myanmar border

Por Höglund, Richard, Moussavi, Younis, Ruengweerayut, Ronnatrai, Cheomung, Anurak, Äbelö, Angela, Na-Bangchang, Kesara
Publicado no Malar J (2016)

Bilirubin—A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy

Por Rekić, Dinko, Clewe, Oskar, Röshammar, Daniel, Flamholc, Leo, Sönnerborg, Anders, Ormaasen, Vidar, Gisslén, Magnus, Äbelö, Angela, Ashton, Michael
Publicado em 2011

Population pharmacokinetic properties of artemisinin in healthy male Vietnamese volunteers

Por Birgersson, Sofia, Van Toi, Pham, Truong, Nguyen Thanh, Dung, Nguyen Thi, Ashton, Michael, Hien, Tran Tinh, Abelö, Angela, Tarning, Joel
Publicado no Malar J (2016)

Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications

Por Hoglund, Richard M, Byakika-Kibwika, Pauline, Lamorde, Mohammed, Merry, Concepta, Ashton, Michael, Hanpithakpong, Warunee, Day, Nicholas P J, White, Nicholas J, Äbelö, Angela, Tarning, Joel
Publicado no Br J Clin Pharmacol (2015)

External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients

Por Rekić, Dinko, Röshammar, Daniel, Bergstrand, Martin, Tarning, Joel, Calcagno, Andrea, D’Avolio, Antonio, Ormaasen, Vidar, Vigan, Marie, Barrail-Tran, Aurélie, Ashton, Michael, Gisslén, Magnus, Äbelö, Angela
Publicado em 2012